Accepted: July 5, 2022

Received in revised form: July 1, 2022

Received: March 3, 2022

Conflict to Disclose: None

Author Contributions:

Griffith: data analysis, original draft

Romanelli: conceptualization, writing, reviewing, and editing

KEY POINTS

Background

Oral antiretrovirals are an effective option for HIV pre-exposure prophylaxis (PrEP) which rely on once daily dosing and strict adherence.

Long-acting injectable agents may be used to achieve PrEP without the need for daily dosing.

Findings

While effective, the only currently approved long-acting agent for PrEP (Cabotegravir LA) must be administered as a single 3 ml gluteal injection which is costly and associated with injection site pain.

While limitations exist, long-acting antiretroviral options afford the potential to transform HIV PrEP.

Pharmacists are uniquely qualified to impact HIV PrEP and by expanding their scope of practice they may be able to further impact the course of the HIV epidemic by preventing new infections.

DOI: https://doi.org/10.1016/j.japh.2022.07.001

© 2022 Published by Elsevier Inc.